Tech Company Financing Transactions
Bolden Therapeutics Funding Round
Bolden Therapeutics closed a $1.5 million Seed investment round on 1/22/2024. Investors included Resolute Ventures, LifeSpan Vision Ventures and Slater Technology Fund.
Transaction Overview
Company Name
Announced On
1/22/2024
Transaction Type
Debt
Amount
$1,500,000
Round
Seed
Investors
Proceeds Purpose
This financing provides important support to enable the company to advance its preclinical development of antisense oligonucleotides to promote neurogenesis.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
225 Dyer Street, Floor 2
Providence, RI 02903
USA
Providence, RI 02903
USA
Phone
Undisclosed
Website
Email Address
Overview
Bolden Therapeutics is developing first-in-class therapeutics to increase neurogenesis (the formation of new brain cells) and improve outcomes in neurological disease. Bolden has established proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory in a proprietary mouse model targeting a novel and specific signaling pathway.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Charles Polsky
Chief Executive Officer
Johnny Page
VP - R & D
Anne Valat
Browse more venture capital transactions:
Prev: 1/22/2024: Marama Labs venture capital transaction
Next: 1/22/2024: Bolt Navigation venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs